Substitution of wheat dried distillers grains with solubles for barley grain or barley silage in feedlot cattle diets: intake, digestibility, and ruminal fermentation

The objective of this study was to evaluate the effects of substituting wheat dried distillers grains with solubles (DDGS) for barley grain and barley silage on intake, digestibility, and ruminal fermentation in feedlot beef cattle. Eight ruminally cannulated Angus heifers (initial BW 455 ± 10.8 kg) were assigned to a replicated 4 × 4 Latin square design with 4 treatments: control, low (25%), medium (30%), and high (35%) wheat DDGS (DM basis). The diets consisted of barley silage, barley concentrate, and wheat DDGS in ratios of 15:85:0 (CON), 10:65:25 (25DDGS), 5:65:30 (30DDGS), and 0:65:35 (35DDGS; DM basis), respectively. The diets were formulated such that wheat DDGS was substituted for both barley grain and barley silage to evaluate whether wheat DDGS can be fed as a source of both energy (grain) and fiber in feedlot finishing diets. Intakes (kg/d) of DM and OM were not different, whereas those of CP, NDF, ADF, and ether extract (EE) were greater (P < 0.01) and intake of starch was less (P < 0.01) for the 25DDGS compared with the CON diet. The digestibilities of CP, NDF, ADF, and EE in the total digestive tract were greater (P < 0.05) for 25DDGS vs. CON. Ruminal pH and total VFA concentrations were not different (P > 0.15) between 25DDGS and CON diets. Replacing barley silage with increasing amounts of wheat DDGS (i.e., from 25DDGS to 35DDGS) linearly reduced (P < 0.05) intakes of DM and other nutrients without altering (P=0.40) CP intake. In contrast, digestibilities of DM and other nutrients in the total digestive tract linearly increased (P < 0.05) with increasing wheat DDGS except for that of EE. Additionally, with increasing amounts of wheat DDGS, mean ruminal pH tended (P=0.10) to linearly decrease, and ruminal pH status decreased with longer (P=0.04) duration of pH <5.5 and <5.2, and greater (P=0.01) curve area under pH <5.8 and <5.5 without altering (P > 0.19) ruminal VFA and NH(3)-N concentrations. Results indicated that wheat DDGS can be effectively used to replace both barley grain and silage at a moderate amount to meet energy and fiber requirements of finishing cattle. However, when silage content of the diet is low (<10%), wheat DDGS is not an effective fiber source, so replacing forage fiber with wheat DDGS in finishing diets decreases overall ruminal pH status even though the rapidly fermentable starch content of the diet is considerably reduced.     

Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas

Background: Progesterone receptor (PR) antagonist aglepristone (RU534) has been used successfully for pregnancy termination and therapy of pyometra, vaginal tumors, and mammary hyperplasia in bitches and queens. All of these conditions share with canine mammary carcinomas the expression of PR. Objectives: To study the effect of RU534 on proliferation and apoptosis in canine mammary carcinomas in relation to PR expression. Animals: Twenty‐seven nonspayed bitches with mammary carcinomas were treated with either 2 doses of 20 mg/kg RU534 (n = 22, RU534‐treated group) or oil placebo (n = 5, control group) on days 1 and 8. Methods: Tumor samples were collected before (day 1) and after (day 15) treatment for immunohistochemistry. PR expression, proliferation index (PI), and apoptotic index (AI) were determined using antibodies against PR, Ki67, and cleaved lamin A/C antigens, respectively. The effect of treatment on these parameters was analyzed. Results: Differential expression of PR between day 1 (59.1% PR‐positive tumors) and day 15 (36.4% PR‐positive tumors) was observed in RU534‐treated tumors exclusively. After RU534 treatment, mean PI was significantly decreased in PR‐positive but unchanged in PR‐negative RU534‐treated tumors. A reduction of ≥20% in PI was found in 61.5% of RU534‐treated tumors with PR expression. Conversely, no effect on AI was observed after RU534 treatment. Conclusions and Clinical Importance: Neoadjuvant RU534 treatment had PR expression‐related inhibiting effects on proliferation of canine mammary carcinoma cells.     

Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis

Feng, Q., Wu, G. H., Liang, T. M., Ji, H. Y., Jiang, X. J., Gu, W., Wang, W. Pharmacokinetics of oxytetracycline in hemolymph from the Chinese mitten crab, Eriocheir sinensis. J. vet. Pharmacol. Therap. 34 , 51–57. The purpose of this study was to investigate the hemolymph kinetics and depuration time of oxytetracycline following intramuscular administration at doses of 2, 8 and 40 mg/kg body weight, respectively. The concentration of OTC in hemolymph was assayed using solid phase extraction and high performance liquid chromatography. The elimination half‐life of the terminal part of the elimination phase (t_1/2β) ranged from 87.9 to 114.3 h. The total body clearance (CL_b) was 0.0430 L/kg/h at the lower dose, 0.0123 L/kg/h at the medium dose and 0.0013 L/kg/h at the higher dose. The apparent volume of the central compartment (V_c) was found to be 1.383, 0.699 and 0.143 L/kg respectively. The depuration time for each dose was 13.6, 29.6 and 57.6 days, respectively. Results from the present study suggest that the 40 mg/kg dose might have the best therapeutic efficacy following intramuscular administration.     

Gait deficits in liver disease: Hepatic encephalopathy and hepatic myelopathy

In this issue, the unusual clinical presentation of a horse diagnosed is described with severe liver cirrhosis and hepatic encephalopathy. The horse initially presented for thoracic and pelvic limb ataxia and weakness, and signs of forebrain disease were not apparent until later in the disease process. The typical pathology of central nervous system disease associated with liver disease is related to encephalopathy and forebrain disease; however, the spinal cord is occasionally also involved. Hepatic myelopathy is a rare syndrome usually associated with surgical or acquired portosystemic shunts, liver cirrhosis and/or portal hypertension in man. Where a gliopathy is the most prominent pathological feature seen in hepatic encephalopathy, in hepatic myelopathy the most remarkable feature is demyelination of the corticospinal tracts of the distal cervical and thoracic spinal cord with occasional axon loss. The clinical signs of hepatic myelopathy are spastic paresis/paralysis with normal sensory findings and preserved sphincter function. The prognosis for hepatic myelopathy is generally poor. In summary, in severe liver disease, motor deficits can occur secondary to the encephalopathy, but motor deficits can also occur as a result of spinal cord pathology such as seen in hepatic myelopathy. In examination of horses with myelopathies, liver disease as a cause of myelopathy should be included in our list of differentials.